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Abstract
Background: The aim of the study was to evaluate the performance of different newly developed and/or commercially
available ELISAs for detection of PRRSV specific antibodies. Consequently, ten PRRSV negative piglets (group V)
were vaccinated with a PRRSV type 2 vaccine. Blood samples were taken before as well as seven, 21 and 42 days after
vaccination. At day 42 after vaccination (day 0 of the study) all of the piglets from group V and 10 non-prevaccinated
PRRSV negative piglets (group N) were challenged with an HP PRRSV type 2 field strain. Blood samples were
taken before and at days 3, 7, 10, 14, 21 and 28 after challenge. The success of vaccination and challenge
was measured with RT qPCR. All serum samples were tested with six ELISAs for detection of PRRSV antibodies. Three
of them are nucleocapsid-based, two use a glycoprotein extract and one uses inactivated whole virus as antigen. The
specificity of the ELISAs was evaluated using 301 serum samples of piglets from PRRSV negative herds.
Results: The piglets from group V tested positive by RT qPCR at day 7 after vaccination and all piglets tested positive
at day 3 after challenge. PRRSV specific antibodies were seen with all nucleocapsid-based ELISAs from day 21 after
vaccination onwards in group V and from day 10 after challenge in group N. The glycoprotein-based ELISAs detected
antibodies from day 42 after vaccination (group V) and day 21 after challenge (group N). The agreement according to
kappa-coefficient was almost perfect. The glycoprotein-based ELISAs were able to distinguish PRRSV type 2, although
with some cross reactions. Regarding specificity, the ELISAs performed differently (specificity between 97.4 % and
100 %), whereas most of the ELISAs with higher sensitivity had a slightly lower specificity.
Conclusions: All tested ELISA were able to detect PRRSV antibodies in the serum of pigs vaccinated with
a PRRSV type 2 vaccine and after challenge with an HP PRRSV type 2 field strain. The onset on antibody
detection differed, depending on the type of antigen used in the ELISAs. Most of the ELISAs with a higher
sensitivity had a lower specificity.
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Background
Detection of antibodies (Ab) against porcine reproductive
and respiratory syndrome virus (PRRSV) is, in addition to
a number of different established PCR methods [1, 2], one
important tool for the monitoring and surveillance of
PRRSV in pig farms [3, 4]. In addition to the cost-effective,
simple and rapid analysis by ELISA, alternative methods,
such as serum neutralization test, immunofluorescence
assay or Western blot are used for special indications
[3, 5–7]. In recent years, several ELISAs for detection
of Ab against PRRSV in pig serum have been developed
[7–9], some of them with the intention of making them
commercially available. Some ELISAs, however, have been
on the market for many years and have been continuously
adapted and improved. Studies have been published valid-
ating and comparing some of them [10–12]. The IDEXX
PRRS X3 Ab test (IDEXX, Westbrook, USA) is usually
used as the gold standard for comparison [8, 9, 13]. Ac-
cording to the manufacturer, this ELISA has a specificity
of 99.9 % and a sensitivity of 98.8 %. Most of the ELISAs
are able to detect Ab against PRRSV type 1 and type 2
[14]. However, some have been described as able to distin-
guish between PRRSV types [5, 7, 13]. The ELISAs pres-
ently used in routine analysis are usually based on the
PRRSV nucleocapsid protein as antigen [15]. For some
indications, ELISAs based on the non-structural proteins
(Nsp) 7 or 9, the membrane glycoprotein 5 (Gp5) and re-
combinant antigens have been designed [8, 9, 16–18].
Most of them are not commercially available.
Some studies are available that give data about the
onset of antibody development after vaccination with
inactivated PRRSV vaccine or live attenuated vaccine as
well as after challenge, measured by different methods
[6, 8, 13]. At this point, no data are available regarding
how newly developed ELISAs that already are or will in
the near future become commercially available, perform
after vaccination with a live attenuated PRRSV type 2 vac-
cine and the challenge of pigs with highly pathogenic (HP)
PRRSV. Furthermore, the scientific community lacks data
about the onset of Ab detection after infection with HP
PRRSV while using some of the ELISAs that have been
commercially available for many years.
The objective of the study was to test the performance
of different commercial and newly developed ELISAs for
the detection of Ab against PRRSV in the serum of pigs
vaccinated with a newly developed PRRSV type 2 attenu-
ated live vaccine, and/or challenged with an HP PRRSV
field strain. Serum samples of PRRSV negative pigs were
analysed to evaluate the specificity of the ELISAs.
Results
Molecular analysis
At the beginning of the study, all of the serum samples
of the piglets from groups V and N tested negative in
PRRSV RT qPCR. On days 7 (first sampling time) and
21 after vaccination (days −35 and −21 of the study), all
of the piglets of group V tested positive in PRRSV RT
qPCR. All of the piglets from both groups developed a
PRRS viremia, detected from day 3 after the challenge
with HP PRRSV onwards.
Detection of PRRSV Ab by ELISA
Serum samples of all piglets from groups V and N were
PRRSVAb negative in all of the tested ELISAs on day −42
(the start of the study). Figure 1 gives an overview of the
S/P or OD values of each ELISA during the whole study.
The number of seropositive samples on each sampling day
tested with all ELISAs is given in Table 1. On day −21 of
the study (21 days after vaccination), a seroconversion was
observed in all piglets from group V, measured with the
INgezim and the QIAGEN ELISA. One sample tested with
the IDEXX ELISA was still PRRSV Ab negative at this
point. The same sample, as well as another one, also tested
negative with the AJ ELISA. These negative samples were
just below the cut-off of the ELISAs. The first seroconver-
sion in group N was observed on day 10 after challenge.
The S/P value of all positive samples measured with the
INgezim were significantly (P < 0.01) higher than in the
other ELISAs, although the cut-off with the INgezim is
the same as with IDEXX and QIAGEN.
A later onset of Ab detection was observed with the
HIPRA A/S compared to the other ELISAs. On day −21,
only one sample from group V was weakly positive. On
day 0, however, all of the piglets from group V were
seropositive and remained so until the end of the study.
The same phenomenon was seen in group N with sero-
conversion on day 21 after challenge, measured with the
HIPRA A/S. Some positive results were found with the
HIPRA E/S throughout the study, especially in cases
with high S/P values detected by the HIPRA A/S.
Several correlations were observed between the S/P
or OD values of all study ELISAs (Table 2). Figure 2
shows the correlation between the IDEXX and INgezim,
QIAGEN and AJ ELISA results over all sampling points
and the correlation between INgezim and QIAGEN
ELISA which was especially high. Both HIPRA ELISAs
correlated on several time points with correlation coef-
ficients up to 0.64. The agreement between the ELISAs,
measured with kappa coefficient (κ), and the correl-
ation of the positive/negative results can be seen in
Table 3. An almost perfect agreement was found be-
tween IDEXX, INgezim, QIAGEN and AJ ELISAs. The
agreement between HIPRA A/S and AJ ELISA was
almost perfect as well. The HIPRA A/S agreed substan-
tially (κ between 0.6 and 0.8) or less than substantially
with the other ELISAs (not shown in the table). The
agreement (κ) of the HIPRA E/S with the other ELISAs
was mostly less than 0.2.
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Table 1 Results of PRRSV Ab ELISAs at the sampling points, number of positive animals
Study day −42 −35 −21 0 3 7 10 14 21 28
Group V n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10
IDEXX 0 0 9 10 9 10 10 10 9 9
INgezim 0 0 10 10 10 10 10 10 10 10
HIPRA A/S 0 0 1 10 10 10 10 10 10 10
HIPRA E/S 0 0 0 0 1 1 3 3 1 3
QIAGEN 0 0 10 10 10 10 10 10 10 10
AJ 0 0 8 10 10 10 10 10 10 10
Group N n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10
IDEXX n.d. n.d. n.d. 0 0 0 6 10 10 10
INgezim n.d. n.d. n.d. 0 0 0 10 10 10 10
HIPRA A/S n.d. n.d. n.d. 0 0 0 0 0 8 10
HIPRA E/S n.d. n.d. n.d. 0 0 0 0 0 1 1
QIAGEN n.d. n.d. n.d. 0 0 0 7 10 10 10
AJ n.d. n.d. n.d. 0 0 0 0 8 10 10
Group V: vaccination with a PRRSV live vaccine at day −42
Groups V and N: challenge with an HP PRRSV field strain at day 0
n.d.: not done
Fig. 1 Boxplots of S/P values, respectively OD values of all PRRSV Ab ELISAs tested. Vaccinated group: vaccination with a PRRSV live vaccine at
day −42 (see arrow), both groups: challenge with an HP PRRSV field strain at day 0 (see arrows), red lines: cut-off of the ELISAs
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Table 4 shows the results of the PRRSV negative sam-
ples and the calculated specificity of the ELISAs. The
false-positive results of the QIAGEN ELISA had S/P
values between 0.40 and 0.55; most were only slightly
above the cut-off. The false-positive samples measured
with the HIPRA A/S were between 22 % and 37 % of the
positive control. No false-positive results were observed
with the AJ.
Discussion
The performance of several newly developed and com-
mercially available ELISAs for detection of PRRSV Ab was
tested in this study using well-defined serum samples of
PRRSV type 2 vaccinated, HP PRRSV type 2 challenged
and negative pigs.
ELISAs that were coated with a similar antigen per-
formed identically. With the nucleocapsid-based ELISAs
IDEXX, INgezim and QIAGEN, a seroconversion was
detected beginning on day 10 after the challenge with a
HP PRRSV type 2 field strain. Antibodies against the nu-
cleocapsid can be detected by the end of the second
week after infection, but are not neutralizing [14]. No
studies have been published regarding the newly devel-
oped INgezim and QIAGEN until now. Both ELISAs
showed a higher sensitivity than the IDEXX by detecting
all serum samples as positive at day 21 after vaccination
and from day 10 after challenge onwards. In a recently
published study, the sensitivity of the IDEXX ELISA was
stated at 80 % in the field samples tested, compared to
the immunoperoxidase monolayer assay (IPMA) [15].
This is in contrast to other studies which stated a sensi-
tivity of the IDEXX ELISA of 100 % in serum samples
21 days after PRRSV inoculation [5] and of 91.5 % in
field samples [7].
The specificity of the QIAGEN ELISA was, at 98.1 %,
lower than the IDEXX which had a 100 % specificity as
has been published previously [5, 7, 12], respectively a
99.9 % specificity, according to the manufacturer. The
Table 2 Correlations between the S/P or OD values of the
PRRSV Ab ELISAs tested using the correlation coefficient after
Spearman
INgezim HIPRA A/S HIPRA E/S QIAGEN AJ
IDEXX 0.84 0.73 0.71 0.89 0.85
INgezim 0.75 0.65 0.92 0.79
HIPRA A/S 0.62 0.73 0.87
HIPRA E/S 0.73 0.75
QIAGEN 0.84
Fig. 2 Scatterplot indicating the correlation between S/P values of study ELISAs. a IDEXX and INgezim ELISA, (b) IDEXX and QIAGEN ELISA,
(c) IDEXX and AJ ELISA, (d) INgezim and QIAGEN ELISA. Green line: line of best fit; red lines: cut-off of the ELISAs
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specificity of the INgezim ELISA was with 99.0 % be-
tween these two ELISAs [12]. Compared to the specifi-
city of 92.3 % of a former version of this ELISA
(INgezim PRRS Universal kit, Ingenasa), the INgezim
ELISA used in our study has been improved consider-
ably [11]. According to another study, specificities of
83 % and 77 % were found in field samples for the
IDEXX ELISA and the INgezim PRRS Universal, re-
spectively, compared to the IPMA [15]. The agreement
between the IDEXX, INgezim and QIAGEN ELISAs was
almost perfect, according to κ [19].
The AJ ELISA which is based on an inactivated virus
performed almost similarly. A later onset of antibody de-
tection with eight out of ten positive samples at day 21
after vaccination in group V and at day 14 after chal-
lenge in group N was seen, possibly depending on the
fact that this first version of the assay allowed IgG anti-
body response detection only. After seroconversion, all
samples remained positive until the end of the study,
testifying a high sensitivity of this ELISA.
The antigens used in the HIPRA ELISAs contain, a
glycoprotein rich extraction of the virus, according to
the manufacturer. The major envelope proteins of the
PRRSV are the GP5 and the M protein [20]. A conform-
ational epitope of GP5 induces the production of neu-
tralizing Ab that can be detected at the earliest four
weeks after infection [14, 21]. This could be one reason
for the late onset of Ab detection in the HIPRA ELISAs
as was assumed to be the case in another study also con-
ducted with this ELISA [17]. On the other hand, the
duration of Ab against glycoproteins detectable by
ELISA is proven to be much longer than in nucleocapsid
based ELISAs [22]. When tested with the HIPRA ELISA,
100 % of the pigs were still Ab positive up to 100 days
post vaccination [17]. We were not able to verify this in
our study, since Ab were only tested for until 28 days
after challenge or 42 days after vaccination, respectively.
Differences between the ELISAs regarding sensitivity
and specificity in field samples have been explained by
the dissimilar characteristics of the antigens used [18].
The slightly delayed onset of PRRSV Ab detection mea-
sured by the AJ ELISA is probably caused by this fact as
well. The specificity of the AJ ELISA was at 100 % higher
than that of the HIPRA A/S at 98.5 % and similar to the
IDEXX ELISA.
The agreement of the HIPRA E/S results with the
other ELISAs is low because of its exclusive detection of
PRRSV type 1 Ab that were not developed in the study
pigs. Despite this exclusive detection of Ab against
PRRSV type 1, some positive samples were found with
the HIPRA E/S in this study after vaccination and/or
challenge with PRRSV type 2. Cross-reactions between
both types could explain these reactions. According to
the manufacturer, a distinction between both genotypes
can be made, if the S/P value of the ELISA in question
(HIPRA A/S or E/S) is less than 30 % of the other. In
our study, S/P values of 12 of the 14 samples found to
be positive with the HIPRA E/S were less than 30 % of
the S/P values of the HIPRA A/S. Therefore, these sam-
ples could be declared as PRRSV type 2 Ab positive. The
other two positive samples were at 32 % and therefore
only slightly above the limit calculated by the manufac-
turer. Some other unspecific cross reactions are possible.
Conclusions
As a conclusion it can be said that all of the ELISAs
tested were able to detect PRRSV specific Ab after vac-
cination with a PRRSV type 2 vaccine and/or challenge
with an HP PRRSV type 2 field strain, although with dif-
fering levels of sensitivity and specificity. The onset of
Table 4 Specificity of three of the tested study ELISAs for
detection of PRRSV antibodies
Positive Negative Total Specificity
QIAGEN 6 304 310 98.1 %
AJ 0 278 278 100 %
HIPRA A/S 5 330 335 98.5 %
Results of group S, group V at day −42 and group N at day 0 included
Table 3 Agreement and correlation between the results of the





INgezim Positive 112 8 120 0.89 0.90
Negative 0 50 50
QIAGEN Positive 110 6 116 0.89 0.90
Negative 2 52 54
AJ Positive 103 3 106 0.85 0.85
Negative 9 55 64
Sum 112 58 170
AJ
HIPRA Positive 89 0 89 0.80 0.81
Negative 17 64 81
QIAGEN Positive 105 11 116 0.85 0.85
Negative 1 53 54
Sum 106 64 170
INgezim
QIAGEN Positive 116 0 116 0.95 0.95
Negative 4 50 54
AJ Positive 106 0 106 0.82 0.83
Negative 14 50 64
Sum 120 50 170
Results of groups V and N included, Correlation coefficient after
Spearman given
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Ab detection by the ELISAs differed, depending on the
antigen component used. This must be considered when
choosing the ELISA. IDEXX and AJ ELISAs distinguish
themselves with a particularly high specificity, the INge-
zim and QIAGEN ELISAs stand out with a high sensitiv-
ity. The HIPRA ELISAs were able to distinguish PRRSV
type 2 related antibodies, although with some limitations
caused by cross reactions.
Methods
Study design, animals and serum samples
Twenty piglets from a PRRSV free farm were included in
the study. Ten of those piglets (group V) were injected
with 2 ml of an attenuated PRRSV type 2 vaccine with the
commercial name “Kyoto Biken” PIGWIN PRRSV2 (Kyoto
Biken, Kyoto, Japan) at the age of three weeks. The highest
ORF5 sequence identity of the Kyoto Biken vaccine to
published sequences was observed for the Kyoto 93
strain (GenBank: AB175724). The ten piglets of group
N remained unvaccinated. At the age of ten weeks,
all 20 study piglets received an intranasal challenge of 2 ml
of an HP PRRSV field strain (Vietnam_PRRSV_AGES/
568-30FC/13; GenBank accession number KM588915).
Serum samples were taken from piglets of group 1 before,
seven and 21 days after vaccination and additionally in all
20 study piglets before and at days three, seven, ten, 14, 21
and 28 after challenge. Housing, animal care and experi-
mental protocol of both trials were approved by the local
ethics committee (Agency of the Government in Lower
Austria, Department of Agrarian Law).
Additionally, serum samples from 301 pigs aged be-
tween seven month and three years from four con-
tinuously monitored PRRSV negative boar studs from
Germany and from one German and one Austrian pig
breeding farm (all belonging to PRRSV category IV ac-
cording to Holtkamp et al. [23]) were tested (group S).
The serum samples of these pigs were obtained dur-
ing routine monitoring. In the farms from which the
samples of group S were derived, the > PRRSV PCR
and ELISA routinely performed did not produce any
positive results.
Detection of PRRSV-RNA by real-time RT-PCR
All serum samples of groups V and N were tested for the
presence of PRRSV RNA by real-time RT-PCR. The RNA
extraction was performed using the Freedom EVO® 150
(Tecan, Grödig, Austria) automated platform, and the
Nucleospin® 96 Virus and the Nucleospin® Virus Core kits
(Macherey-Nagel, GenXpress, Wiener Neudorf, Austria)
following the manufacturers’ instructions. The samples
were then analysed with a commercial real-time RT-PCR
assay for simultaneous detection and differentiation be-
tween PRRSV type 1 and type 2 genotypes (TaqMan® NA
and EU PRRSV Reagents and Controls, ThermoFisher
Scientific, Vienna, Austria) as described previously [12].
Detection of PRRSV antibodies by ELISA
All of the serum samples from groups V and N were
tested for antibodies against PRRSV by the following
indirect ELISAs: a) IDEXX PRRS X3 Ab ELISA – in
the following called IDEXX, b) INgezim PRRS 2.0
(Ingenasa, Madrid, Spain) – INgezim, c) Civtest suis
PRRS A/S plus (Laboratorios HIPRA, Amer, Spain) –
HIPRA A/S, d) Civtest suis PRRS E/S plus (Laboratorios
HIPRA) – HIPRA E/S, e) pigtype® PRRSV Ab (QIAGEN,
Leipzig, Germany) – QIAGEN and f) PRRSV CHECK
ELISA (Analytik Jena, aj Roboscreen, Leipzig, Germany) –
AJ. All ELISAs tested are commercially available.
In order to determine the specificity, all 301 serum sam-
ples of group S were tested with the HIPRA A/S ELISA,
276 of them with the QIAGEN ELISA and 244 of them
with the AJ ELISA. Specificity data for the other tested
ELISAs, determined with the same sample panel, were
published previously [12].
The IDEXX, INgezim and QIAGEN ELISAs are based
on the nucleocapsid as antigen [15]. The cut-off for
these ELISA was calculated at a sample/positive (S/P)
value of 0.4. The HIPRA ELISAs are coated with a
glycoprotein rich extract as antigen which is produced
by obtaining whole PRRS virus particles with envelope
from a non-cell associated PRRSV culture with subsequent
solubilizing of glycoproteins with detergents, according to
the manufacturer. The cut-off is determined at 20 % of
the positive control OD value. The AJ ELISA is based on
a coating with inactivated virus, according to the manufac-
turer. Samples with OD values > 0.5 measured with the AJ
ELISA were defined as positive. To be valid, the OD value
of the positive control had to be > 1.0 and the OD value of
the negative control must be < 0.25. All ELISAs were per-
formed according to manufacturers’ instructions.
Statistical analysis
The results of the ELISAs measured in the serum samples
of group V and N were described as positive and negative
for PRRSV antibodies. Additionally, the median, quartiles
and 95 % confidence interval of S/P or OD values for each
sampling point were evaluated and pictured in boxplots.
The correlation coefficient after Spearman was used to
test for correlations between the S/P or OD values of the
ELISAs and for correlation of the positive and negative re-
sults. The agreement between the ELISAs was calculated
with the kappa coefficient (κ) using the results of groups
V and N and interpreted according to Landis and Koch
[19]. The specificity of the ELISAs was determined using
the pre-study samples from group V (before vaccination)
and group N (before challenge) and all of the samples
from group S.
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